PK Med
Develops injectable biodegradable micro-implants for local drug delivery in rheumatology and hematology
Highlights
- New on EvolcAdded 2026-11-02
About PK Med
PK MED develops injectable, biodegradable micro-implants that deliver drugs at the site of disease. Its early programs are ARTHRELIS, a local treatment for refractory gout flares, and ENGRAFTIS, a local therapy intended to improve bone marrow graft.
The company is a privately owned French biotech established in 2019 by Truffle Capital. It is focused on drug delivery for rheumatology and hematology indications and is presented as an early-stage portfolio of two programs.
The company is headquartered in Paris, France, and its legal form is SA. Its management team includes a CEO, a CFO and a Director of R&D, and it has a scientific advisory board.
Product: Injectable biodegradable micro-implants for local drug delivery (ARTHRELIS and ENGRAFTIS programs)
Jobs at PK Med
Leadership
- Farah Marzouki · CEOSource: company website
- Charles Sanson · CFOSource: company website
More biotech & pharma companies
Poietis
Laser-assisted bioprinting systems for research laboratories and clinical tissue manufacturersNew on EvolcPromise Proteomics
Mass spectrometry protein and monoclonal antibody quantification products for clinical and bioanalytical laboratoriesNew on EvolcProteogenix
Antibody discovery, engineering and early-development services for biotech, pharmaceutical, diagnostic, veterinaryNew on EvolcProvepharm
Develops medical dyes for healthcare professionals performing precision surgery and clinical proceduresNew on EvolcQubit Pharmaceuticals
Develops AI- and quantum-enabled drug discovery tools and therapeutics for pharmaceutical partners and patients with major diseasesNew on EvolcRoowin
Fine chemistry and cGMP drug-development services for pharmaceutical, biotechnology, and fine chemical companiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
